Prostatype Genomics News Today

/PRNewswire/ -- Prostatype Genomics is currently conducting a study of 160 patients together with seven leading Spanish hospitals and the Spanish National...

Prostatype Genomics AB announces today the final outcome of the share issue with preferential rights for the Companys shareholders whose subscription period ended on 11 May 2023. The subscription... | May 16, 2023

/PRNewswire/ -- Prostatype Genomics AB announced today that Professor Gerald Andriole has been appointed as global Chief Medical Officer at Prostatype Genomics....

With effect from April 27, 2023, the subscription rights in Prostatype Genomics AB will be traded on First North Growth Market. Trading will continue up until and including May 08, 2023. Instrument:

Prostatype Genomics AB has recruited Steven Gaal to the role of President of the companys wholly owned subsidiary, Prostatype Genomics Inc. Stevens task will be to establish and launch Prostatype®, the companys genomic test to assess the aggressiveness of prostate cancer in individual patients, in the US market. Steven has over 18 years of experience from leading positions in the sale of cancer diagnostic tools and services and begins his employment with Prostatype Genomics Inc. effective immed...

Prostatype Genomics and Life Genomics start a non-exclusive collaboration meaning Life Genomics will handle all steps in the laboratory process required to analyse Prostatype®, Prostatype Genomics gene test to assess the aggressiveness of prostate cancer. The collaboration means that Prostatype Genomics can further focus on marketing the test to patients and doctors and secures resources to be able to handle the increased demand for Prostatype® from patients and healthcare. The agreement appli...

-Prostatype® prostate cancer test made available for patients in UK & Ireland

Prostatype Genomics AB has today published its quarterly report for the sixth quarter of the extended financial year comprising the period from 1 October 2020 to 31 December 2020, and the year end report for the extended financial year. The extended financial year covers the period from 1 July 2019 to 31 December 2020. The report is available on the company website.